XML 14 R4.htm IDEA: XBRL DOCUMENT v3.22.1
Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2022
Mar. 31, 2021
Income Statement [Abstract]    
Net Revenue $ 7,811,223 $ 5,009,436
Cost of goods sold 805,081 474,433
Gross profit 7,006,142 4,535,003
Operating expenses    
Selling, general and administrative expenses 9,375,630 5,409,730
Research and development 204,637 118,212
Depreciation and amortization 202,747 90,591
Total operating expenses 9,783,014 5,618,533
Operating loss (2,776,872) (1,083,530)
Other expense    
Interest expense (711)
Share of losses from equity method investment (379,633) (99,135)
Total other expense (379,633) (99,846)
Net loss (3,156,505) (1,183,376)
Less: Net loss attributable to noncontrolling interest (27,181) (1,632)
Net loss attributable to Sanara MedTech common shareholders $ (3,129,324) $ (1,181,744)
Net loss per share of common stock, basic and diluted $ (0.41) $ (0.17)
Weighted average number of common shares outstanding, basic and diluted 7,606,450 6,816,646